Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Antimicrobial use among patients receiving palliative care consultation.

Chun ED, Rodgers PE, Vitale CA, Collins CD, Malani PN.

Am J Hosp Palliat Care. 2010 Jun;27(4):261-5. doi: 10.1177/1049909109352336.

PMID:
19959846
2.

Piperacillin/tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital.

Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P.

Diagn Microbiol Infect Dis. 1998 Jun;31(2):355-68.

PMID:
9635910
4.

The pattern of antimicrobial use for palliative care in-patients during the last week of life.

Abduh Al-Shaqi M, Alami AH, Zahrani AS, Al-Marshad B, Muammar AB, M Z AS.

Am J Hosp Palliat Care. 2012 Feb;29(1):60-3. doi: 10.1177/1049909111406900.

PMID:
21676985
5.

Point prevalence survey of antimicrobial utilization in the cardiac and pediatric critical care unit.

Blinova E, Lau E, Bitnun A, Cox P, Schwartz S, Atenafu E, Yau Y, Streitenberger L, Parshuram CS, Marshall J, Seto W.

Pediatr Crit Care Med. 2013 Jul;14(6):e280-8. doi: 10.1097/PCC.0b013e31828a846d.

PMID:
23823209
7.

Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.

DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H.

Antimicrob Agents Chemother. 2005 Aug;49(8):3217-21.

8.

Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens.

Paterson DL, Muto CA, Ndirangu M, Linden PK, Potoski BA, Capitano B, Bonomo RA, Aron DC, Donskey CJ.

Antimicrob Agents Chemother. 2008 Feb;52(2):465-9.

9.

Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).

Amara S, Adamson RT, Lew I, Huang X.

Curr Med Res Opin. 2013 Jul;29(7):869-77. doi: 10.1185/03007995.2013.803056.

PMID:
23659559
10.
11.

Rates and appropriateness of antimicrobial prescribing at an academic children's hospital, 2007-2010.

Levy ER, Swami S, Dubois SG, Wendt R, Banerjee R.

Infect Control Hosp Epidemiol. 2012 Apr;33(4):346-53. doi: 10.1086/664761.

PMID:
22418629
12.

The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.

Yost RJ, Cappelletty DM; RECEIPT Study group..

Pharmacotherapy. 2011 Aug;31(8):767-75. doi: 10.1592/phco.31.8.767.

PMID:
21923603
13.

Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V, Teppler H; Protocol 017 Study Group..

Ann Surg. 2003 Feb;237(2):235-45.

14.

Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.

Marie JP, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, Baudard M, Legrand O, Rio B, Delmer A, Zittoun R.

Support Care Cancer. 1999 Mar;7(2):89-94.

PMID:
10089089
15.

Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.

Siami G, Christou N, Eiseman I, Tack KJ; Severe Skin and Soft Tissue Infections Study Group..

Antimicrob Agents Chemother. 2001 Feb;45(2):525-31.

16.

Antimicrobial use in patients with advanced cancer receiving hospice care.

White PH, Kuhlenschmidt HL, Vancura BG, Navari RM.

J Pain Symptom Manage. 2003 May;25(5):438-43.

PMID:
12727041
17.

Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.

Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA.

Antimicrob Agents Chemother. 2002 Mar;46(3):854-8.

18.

Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.

Pillay T, Pillay DG, Adhikari M, Sturm AW.

Am J Perinatol. 1998 Jan;15(1):47-51.

PMID:
9475688
19.

Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, Weber SG.

Antimicrob Agents Chemother. 2005 Nov;49(11):4555-60.

20.

Investigation of antimicrobial use pattern in the intensive treatment unit of a teaching hospital in western Nepal.

Shankar PR, Partha P, Shenoy N, Brahmadathan KN.

Am J Infect Control. 2003 Nov;31(7):410-4.

PMID:
14639438
Items per page

Supplemental Content

Support Center